|
Actinium Pharmaceuticals, Inc. (ATNM): Marketing Mix [Jan-2025 Updated]
US | Healthcare | Biotechnology | AMEX
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Actinium Pharmaceuticals, Inc. (ATNM) Bundle
In the cutting-edge world of precision oncology, Actinium Pharmaceuticals, Inc. (ATNM) emerges as a pioneering force, revolutionizing cancer treatment through its innovative radioimmunotherapeutic technologies. By harnessing the power of targeted alpha-particle therapy and developing breakthrough treatments like Iomab-B, this New York-based biotech company is transforming how we approach challenging hematologic malignancies, particularly for elderly patients with relapsed/refractory acute myeloid leukemia (AML). Dive into the strategic marketing landscape that positions Actinium at the forefront of personalized cancer care, exploring how their unique product, strategic placement, targeted promotion, and sophisticated pricing model are reshaping the future of oncological treatments.
Actinium Pharmaceuticals, Inc. (ATNM) - Marketing Mix: Product
Targeted Radiotherapeutics Development
Actinium Pharmaceuticals specializes in developing precision cancer treatments using radioactive isotopes.
| Product Category | Details |
|---|---|
| Primary Technology | Alpha-particle radiotherapeutic technologies |
| Key Isotopes | Actinium-225 and Bismuth-213 |
| Primary Target | Cancer treatment |
Lead Product: Iomab-B
Iomab-B is designed for elderly patients with relapsed/refractory Acute Myeloid Leukemia (AML).
- Target patient population: Patients aged 55 and older
- Indication: Relapsed/refractory AML
- Clinical stage: Phase 3 clinical trials
Product Pipeline
| Product | Target Indication | Development Stage |
|---|---|---|
| Iomab-B | AML Patient Bridge to Bone Marrow Transplant | Phase 3 |
| Actimab-A | AML First-Line Treatment | Phase 1b/2 |
| Actimab-M | Myelodysplastic Syndrome | Preclinical |
Technological Specialization
Focuses on radioimmunotherapeutic treatments utilizing alpha-particle emission technologies.
- Precision targeting of cancer cells
- Minimal damage to surrounding healthy tissue
- Potential for improved patient outcomes
Actinium Pharmaceuticals, Inc. (ATNM) - Marketing Mix: Place
Headquarters and Geographic Presence
Actinium Pharmaceuticals, Inc. is headquartered at 275 Madison Avenue, 7th Floor, New York City, NY 10016, United States.
Primary Market Reach
North American Oncology Market Focus
| Geographic Region | Market Concentration | Primary Target Facilities |
|---|---|---|
| United States | 90% of clinical operations | Comprehensive Cancer Centers |
| Canada | 10% of clinical operations | Regional Cancer Treatment Centers |
Clinical Trial Distribution
Research Institutions Engaged in Clinical Trials:
- Memorial Sloan Kettering Cancer Center
- MD Anderson Cancer Center
- Dana-Farber Cancer Institute
- University of Pennsylvania
- City of Hope National Medical Center
Distribution Channels
| Channel Type | Percentage of Distribution | Facility Types |
|---|---|---|
| Direct Hospital Sales | 65% | Specialized Cancer Treatment Centers |
| Oncology Research Institutions | 25% | Academic Medical Centers |
| Specialized Pharmaceutical Distributors | 10% | Oncology-focused Distributors |
Clinical Trial Geographic Spread
Active Clinical Trial Locations
- Northeast United States: 40% of trials
- West Coast United States: 30% of trials
- Midwest United States: 20% of trials
- Canada: 10% of trials
Actinium Pharmaceuticals, Inc. (ATNM) - Marketing Mix: Promotion
Conference Presentations
Actinium Pharmaceuticals presents research at key oncology conferences, including:
| Conference | Year | Presentations |
|---|---|---|
| American Society of Hematology (ASH) | 2023 | 4 scientific presentations |
| American Association for Cancer Research (AACR) | 2023 | 3 research abstracts |
Investor Relations and Scientific Communication
Communication channels include:
- Quarterly earnings calls
- Investor presentations
- Scientific publications in peer-reviewed journals
Medical and Scientific Marketing
Targeted marketing strategies focus on:
- Oncology specialists
- Hematology researchers
- Academic medical centers
Community Outreach
| Outreach Channel | Engagement Metrics |
|---|---|
| Scientific webinars | 12 hosted in 2023 |
| Investor conferences | 6 participated in 2023 |
Clinical Trial Communication
Press release distribution metrics:
- Total press releases in 2023: 15
- Clinical trial progress updates: 8 releases
- Average press release reach: 50,000 viewers
Actinium Pharmaceuticals, Inc. (ATNM) - Marketing Mix: Price
Precision Cancer Therapy Pricing Dynamics
Actinium Pharmaceuticals, Inc. operates in the high-value precision cancer therapy market with specialized radioimmunotherapeutic solutions.
| Financial Metric | 2023 Value |
|---|---|
| Research & Development Expenses | $41.3 million |
| Net Loss | $54.2 million |
| Cash and Cash Equivalents | $89.7 million |
Pricing Strategy Components
Key Pricing Strategy Elements:
- Advanced targeted therapeutic treatment pricing model
- Premium pricing approach for innovative radioimmunotherapies
- Reimbursement strategies through healthcare insurance channels
Reimbursement Considerations
Pricing influenced by clinical trial outcomes and potential regulatory approvals for breakthrough cancer treatments.
| Clinical Trial Stage | Potential Pricing Impact |
|---|---|
| Phase I/II Trials | Preliminary pricing assessment |
| Phase III Trials | Definitive pricing strategy development |
| FDA Approval Potential | Full market pricing implementation |
Market Positioning
Pricing strategy aligned with high-value precision oncology market segment, targeting specialized therapeutic interventions.